ANCN vs. IMRX, GBIO, HOWL, CNTB, ELYM, NRXP, FGEN, IMMX, GANX, and KRON
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Immuneering (IMRX), Generation Bio (GBIO), Werewolf Therapeutics (HOWL), Connect Biopharma (CNTB), Eliem Therapeutics (ELYM), NRx Pharmaceuticals (NRXP), FibroGen (FGEN), Immix Biopharma (IMMX), Gain Therapeutics (GANX), and Kronos Bio (KRON). These companies are all part of the "medical" sector.
Anchiano Therapeutics vs.
Immuneering (NASDAQ:IMRX) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
67.7% of Immuneering shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 25.0% of Immuneering shares are owned by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Immuneering presently has a consensus price target of $12.80, indicating a potential upside of 503.77%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immuneering is more favorable than Anchiano Therapeutics.
Anchiano Therapeutics has lower revenue, but higher earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
Anchiano Therapeutics received 26 more outperform votes than Immuneering when rated by MarketBeat users. However, 66.67% of users gave Immuneering an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote.
Immuneering has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
In the previous week, Immuneering had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for Immuneering and 0 mentions for Anchiano Therapeutics. Immuneering's average media sentiment score of 0.61 beat Anchiano Therapeutics' score of 0.00 indicating that Immuneering is being referred to more favorably in the media.
Anchiano Therapeutics' return on equity of 36.08% beat Immuneering's return on equity.
Summary
Immuneering beats Anchiano Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ANCN) was last updated on 1/21/2025 by MarketBeat.com Staff
